1. Sung H, Ferlay J, Siegel R, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA CANCER J CLIN. 2021;71: 209-249.
2. Chu K, Dupuy D. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat. Rev. Cancer. 2014;14: 199-208.
3. Yoshida S, Kornek M, Ikenaga N, Schmelzle M, Masuzaki R, Csizmadia E, Wu Y, Robson S, Schuppan D. Heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma. Hepatology. 2013; 58: 1667-1680.
4. Dumolard L, Ghelfi J, Roth G, Decaens T, Macek Jilkova Z. Percutaneous Ablation-Induced Immunomodulation in Hepatocellular Carcinoma. Int. J. Mol. Sci. 2020; 21: 4398.
5. Su T, Liao J, Dai Z, Xu L, Chen S, Wang Y, Peng Z, Zhang Q, Peng S, Kuang M. Stress-induced phosphoprotein 1 mediates hepatocellular carcinoma metastasis after insufficient radiofrequency ablation. Oncogene. 2018; 37: 14-27.
6. Lam V, Ng K, Chok K, Cheung T, Yuen J, Tung H, Tso W, Fan S, Poon R. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J. Am. Coll. Surg. 2008; 207: 20-29.
7. Zhao Z, Wu J, Liu X, Liang M, Zhou X, Ouyang S, Yao L, Wang L, Luo B. Insufficient radiofrequency ablation promotes proliferation of residual hepatocellular carcinoma via autophagy. Cancer Lett. 2018; 421: 73-81.
8. Kong J, Kong L, Kong J, Ke S, Gao J, Ding X, Zheng L, Sun H, Sun W. After insufficient radiofrequency ablation, tumor-associated endothelial cells exhibit enhanced angiogenesis and promote invasiveness of residual hepatocellular carcinoma. J. Transl. Med. 2012; 10: 230.
9. Nijkamp M, van der Bilt J, de Bruijn M, Molenaar I, Voest E, Diest P, Kranenburg O, Borel Rinkes I. Accelerated perinecrotic outgrowth of colorectal liver metastases following radiofrequency ablation is a hypoxia-driven phenomenon. Ann. Surg. 2009;249: 814-823.
10. Iwahashi S, Shimada M, Utsunomiya T, Imura S, Morine Y, Ikemoto T, Takasu C, Saito Y, Yamada S. Epithelial-mesenchymal transition-related genes are linked to aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation. Cancer Lett. 2016; 375: 47-50.
11. Tan L, Chen S, Wei G, Li Y, Liao J, Jin H, Zou Y, Huang M, Peng Z, Guo Y, Peng S, Xu L, Kuang M. Sublethal heat treatment of hepatocellular carcinoma promotes intrahepatic metastasis and stemness in a VEGFR1-dependent manner. Cancer Lett. 2019; 460: 29-40.
12. Zhang N, Wang L, Li D, Ma D, Wang C, He X, Gao D, Wang L, Zhao Y. TangInterferon-alpha Combined with Herbal Compound "Songyou Yin" Effectively Inhibits the Increased Invasiveness and Metastasis by Insufficient Radiofrequency Ablation of Hepatocellular Carcinoma in an Animal Model. Integr. cancer ther. 2018; 17:1260-1269.
13. Zhang N, Li H, Qin C, Ma D, Zhao Y, Zhu W, Wang L. Insufficient radiofrequency ablation promotes the metastasis of residual hepatocellular carcinoma cells via upregulating flotillin proteins. J. Cancer Res. Clin. Oncol. 2019; 145: 895-907.
14. Kong J, Yao C, Ding X, Dong S, Wu S, Sun W, Zheng L. ATPase Inhibitory Factor 1 Promotes Hepatocellular Carcinoma Progression After Insufficient Radiofrequency Ablation, and Attenuates Cell Sensitivity to Sorafenib Therapy. Front. Oncol. 2020; 10:1080.
15. Chen L, Ma X, Liu X, Cui X. Sorafenib combined with radiofrequency ablation as treatment for patients with hepatocellular carcinoma: a systematic review and meta-analysis. J. BUON. 2017; 22: 1525-1532.
16. Sanz M, Grimwade D, Tallman M, Lowenberg B, Fenaux P, Estey E, Naoe T, Lengfelder E, Dohner H, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009; 113:1875-1891.
17. Sadaf N, Kumar N, Ali M, Ali V, Bimal S, Haque R. Arsenic trioxide induces apoptosis and inhibits the growth of human liver cancer cells. Life Sci. 2018; 205: 9-17.
18. Wei J, Ye C, Liu F, Wang W. All-trans retinoic acid and arsenic trioxide induce apoptosis and modulate intracellular concentrations of calcium in hepatocellular carcinoma cells. J. chemother. 2014; 26: 348-352.
19. Wang G, Zhang W, Fang Z, Zhang W, Yang M, Yang G, Li S, Zhu L, Wang L, Zhang W, et al. Arsenic trioxide: marked suppression of tumor metastasis potential by inhibiting the transcription factor Twist in vivo and in vitro. J. Cancer Res. Clin. Oncol. 2014; 140: 1125-36.
20. Huang Y, Zhou B, Luo H, Mao J, Huang Y, Zhang K, Mei C, Yan Y, Jin H, Su Z, et al. ZnAs@SiO2 nanoparticles as a potential anti-tumor drug for targeting stemness and epithelial-mesenchymal transition in hepatocellular carcinoma via SHP-1/JAK2/STAT3 signaling. Theranostics. 2019; 9: 4391-4408.
21. Qiu Y, Dai Y, Zhang C, Yang Y, Jin M, Shan W. Arsenic trioxide reverses the chemoresistance in hepatocellular carcinoma: a targeted intervention of 14-3-3eta/NF-kappaB feedback loop. J. Exp. Clin. cancer Res. 2018; 37: 321.
22. Yu G, Chen X, Chen S,Ye W, Hou K, Liang M. Arsenic trioxide reduces chemo-resistance to 5-fluorouracil and cisplatin in HBx-HepG2 cells via complex mechanisms. Cancer Cell Int. 2015; 15: 116.
23. Liu B, Pan S, Dong X, Qiao H, Jiang H, Krissansen G. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci. 2006; 97: 675-681.
24. Huang W, Zeng Y. A candidate for lung cancer treatment: arsenic trioxide. Clin. Transl. Oncol. 2019; 21:1115-1126.
25. Fu X, Liang Q, Luo R, Li Y, Xiao X, Yu L, Shan W, Fan G, Tang Q. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment. J. Mater. Chem. B, 2019; 7: 3088-3099.
26. Wu Q, Chen X, Wang P, Wu Q, Qi X, Han X, Chen L, Meng X, Xu K. Delivery of Arsenic Trioxide by Multifunction Nanoparticles to Improve the Treatment of Hepatocellular Carcinoma. ACS Appl. Mater. Interfaces. 2020; 12: 8016-8029.
27. Wang L, Zhang J, An Y, Wang Z, Liu J, Li Y, Zhang D. A study on the thermochemotherapy effect of nanosized As2O3/MZF thermosensitive magnetoliposomes on experimental hepatoma in vitro and in vivo. Nanotechnology. 2011; 22: 315102.
28. Lee S, Lee O, O'Halloran T, Schatz G, Nguyen S. Triggered Release of Pharmacophores from [Ni(HAsO3)]-Loaded Polymer-Caged Nanobin Enhances Pro-apoptotic Activity: A Combined Experimental and Theoretical Study. ACS Nano. 2011; 5: 3961-3969.
29. Zhao Z, Zhang H, Chi X, Li H, Yin Z, Huang D, Wang X, Gao J. Silica nanovehicles endow arsenic trioxide with an ability to effectively treat cancer cells and solid tumors. J. Mater. Chem. B. 2014; 2: 6313-6323.
30. Panahi Y, Farshbaf M, Mohammadhosseini M, Mirahadi M, Khalilov R, Saghfi S, Akbarzadeh A. Recent advances on liposomal nanoparticles: synthesis, characterization and biomedical applications. Artif. Cells Nanomed. Biotechnol. 2017;45: 788-799.
31. Yang J, Yang Y. Metal-Organic Frameworks for Biomedical Applications. Small. 2020; 16: 1906846.
32. Gao L, Chen Q, Gong T, Liu J, Li C. Recent advancement of imidazolate framework (ZIF-8) based nanoformulations for synergistic tumor therapy. Nanoscale. 2019; 11: 21030-21045.
33. Zheng H, Zhang Y, Liu L,Wan W, Guo P, Nyström A, Zou X. One-pot Synthesis of Metal–Organic Frameworks with Encapsulated Target Molecules and Their Applications for Controlled Drug Delivery. J. Am. Chem. Soc. 2016; 138: 962-968.
34. Yan J, Liu C, Wu Q, Zhou J, Xu X, Zhang L, Wang D, Yang F, Zhang H. Mineralization of pH-Sensitive Doxorubicin Prodrug in ZIF-8 to Enable Targeted Delivery to Solid Tumors. Anal. Chem. 2020; 92: 11453-11461.
35. Chen T, Yi J, Zhao Y, Chu X. Biomineralized Metal–Organic Framework Nanoparticles Enable Intracellular Delivery and Endo-Lysosomal Release of Native Active Proteins. J. Am. Chem. Soc. 2018; 140: 9912-9920.
36. Wang H, Chen Y, Wang H, Liu X, Zhou X, Wang F. DNAzyme-Loaded Metal-Organic Frameworks (MOFs) for Self-Sufficient Gene Therapy. Angew. Chem. Int. Ed. Engl. 2019; 58: 7380-7384.
37. Schnabel J, Ettlinger R, Bunzen H. Zn-MOF-74 as pH-Responsive Drug-Delivery System of Arsenic Trioxide. ChemNanoMat. 2020; 6: 1229-1236.
38. Tao W, Zhu X, Yu X, Zeng X, Xiao Q, Zhang X, Ji X, Wang X, Shi J, Zhang H, et al. Black Phosphorus Nanosheets as a Robust Delivery Platform for Cancer Theranostics. Adv. Mater. 2017; 29: 1603276.
39. Martinson C, Reddy K. Adsorption of arsenic(III) and arsenic(V) by cupric oxide nanoparticles. J. Colloid Interface Sci. 2009; 336: 406-411.
40. Poch F, Rieder C, Ballhausen H, Knappe V, Ritz J, Gemeinhardt O, Kreis M, Lehmann, K. The vascular cooling effect in hepatic multipolar radiofrequency ablation leads to incomplete ablation ex vivo. Int. J. Hyperthermia. 2016; 32: 749-756.
41. Berber E, Siperstein A. Local recurrence after laparoscopic radiofrequency ablation of liver tumors: an analysis of 1032 tumors. Ann. Surg. Oncol. 2008; 15: 2757-2764.
42. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010; 52: 762-773.
43. Kim K, Lee J, Klotz E, Kim S, Kim S, Kim J, Han J, Choi B. Safety margin assessment after radiofrequency ablation of the liver using registration of preprocedure and postprocedure CT images. AJR. Am. J. Roentgenol. 2011; 196: 565-572.
44. Dongre A, Weinberg R. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell Biol. 2019; 20: 69-84.
45. Fang J, Islam W, Maeda H. Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers. Adv. Drug Deliv. Rev. 2020; 157: 142-160.
46. Ojha T, Pathak V, Shi Y, Hennink W, Moonen C, Storm G, Kiessling F, Lammers T. Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors. Adv. Drug Deliv. Rev. 2017; 119: 44–60.